Probiotic composition comprising the novel isolated bacterial strain of brevibacterium casei AP9

Patent metadata

Field	Value
Publication number	US-10058575-B2
Application number	US-201414913497-A
Country	US
Kind code	B2
Filing date	Aug 22, 2014
Priority date	Aug 22, 2013
Publication date	Aug 28, 2018
Grant date	Aug 28, 2018

Abstract

The present invention discloses a novel isolated bacterial strain exhibiting probiotic properties. More particularly, the invention discloses a probiotic composition comprising Brevibacterium casei AP9 MCC0012 having improved pH and bile tolerance and improved antimicrobial properties as well as possessing cholesterol reduction property.

First claim

The invention claimed is:

1. A probiotic composition comprising an isolated bacterial strain of Brevibacterium casei AP9, deposited at NCCS, Pune, India under the Budapest Treaty, and having accession number MCC0012, and a hydrocolloid, and optionally, one or more additional probiotic organisms that enhance the probiotic activity of the Brevibacterium casei MCC0012.

2. The probiotic composition as claimed in claim 1 , wherein the composition comprises the one or more additional probiotics and the one or more additional probiotics are selected from the group consisting of L. plantarum ATCC number 8014 , L. fermentum ATCC number 9338 , L acidophillus ATCC number 11975 , L. casei ATCC number 335 , L. bulgarius ATCC number 8001 , L. lactis ATCC number 10705 , L. lechimanni ATCC number 4797 and Bacillus cereus ATCC number JN183063.

3. The probiotic composition as claimed in claim 1 , wherein the hydrocolloid is selected from the group consisting of alginate, whey protein, gelatin, and carrageenan.

4. The probiotic composition as claimed in claim 1 , wherein the composition is in solid, liquid or semisolid form.

5. The probiotic composition as claimed in claim 1 , wherein the composition comprises 10 5 to 10 9 CFU/ml of Brevibacterium casei AP9 MCC0012.

6. The probiotic composition as claimed in claim 1 , wherein the composition comprises 0.01 to 99.9% Brevibacterium casei MCC0012.

7. A method of providing probiotic therapy for reducing extracellular cholesterol, which comprises administering to a subject in need thereof a therapeutically effective amount of a composition that comprises Brevibacterium casei AP9 MCC0012.

8. The method of claim 7 , wherein the composition further comprises a hydrocolloid.

9. The method of claim 7 , wherein the composition further comprises one or more additional probiotic organisms that enhance the probiotic activity of the Brevibacterium casei AP9 MCC0012.

10. The method of claim 7 , wherein the composition further comprises both a hydrocolloid and one or more additional probiotic organisms that enhance the probiotic activity of the Brevibacterium casei AP9 MCC0012.

Assignees

• Council Scient Ind Res

Inventors

• Mungi Hrishikesh Vinayak
• Ghushe Pooja Vijay
• Sunder Avinash Vellore
• Pundle Archana Vishnu

Classifications

• A61P3/06

  Antihyperlipidemics · CPC title

• A61K35/741 Primary

  Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06) · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A23L33/135

  Bacteria or derivatives thereof, e.g. probiotics · CPC title